Title: CGRP Antagonists  
Policy #: Rx.01.207

Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications may be subject to precertification, age, quantity, or formulary restrictions (ie limits on non-preferred drugs). Individual member benefits must be verified.

This pharmacy policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety, or FDA approval may have changed. This Pharmacy Policy will be regularly updated as scientific and medical literature becomes available. This information may include new FDA-approved indications, withdrawals, or other FDA alerts. This type of information is relevant not only when considering whether this policy should be updated, but also when applying it to current requests for coverage.

Members are advised to use participating pharmacies in order to receive the highest level of benefits.

Intent:
The intent of this policy is to communicate the medical necessity criteria for erenumab (Aimovig™), fremanezumab (Ajovy™), or galcanezumab (Emgality™) as provided under the member’s prescription drug benefit.

Description:
Migraine is a recurrent throbbing disabling headache disorder that usually affects one side of the head and is in many cases preceded by warning symptoms. Common symptoms include nausea, photophobia, and phonophobia. The head pain is usually severe and can last for hours or even days.

Calcitonin gene-related peptide (CGRP) is found in neurons of the cerebral cortex, hippocampus, cerebellum, thalamic nuclei and brainstem nuclei and some other sites. In migraines, CGRP is released from trigeminal nerves (the nerves associated with feeling of pain in the head and face), bind to specific receptors, and cause symptoms such as vasodilation, pain, and inflammation. Pain is transmitted from trigeminal ganglion to trigeminal nucleus and then higher central nervous system centers. This accounts for pain, photophobia, and phonophobia.

Therapy for migraine may be abortive, to stop the headache, or prophylactic, to reduce frequency of headaches, number of headache days, or severity of headaches. Current treatment options for prophylaxis of episodic and chronic migraine headaches include: topiramate, valproic acid, beta blockers, and some classes of antidepressants. Onabotulinumtoxin A (Botox) is also an option for prophylaxis of chronic migraines.

The CGRP antagonists are human monoclonal antibodies that selectively bind the CGRP receptors (erenumab) or antagonize calcitonin gene-related peptide (galcanezumab, fremanezumab) to reduce
CGRP. The monoclonal antibodies have shown efficacy in clinical trials by acting at several sites in the trigeminal system and in the CNS which results in pain relief.

Erenumab (Aimovig™), fremanezumab (Ajovy™), and galcanezumab (Emgality™) are indicated for the preventive treatment of migrains in adults. It is unknown if these agents are safe and effective in children under the age of 18.

**Policy:**

**INITIAL CRITERIA**

Erenumab (Aimovig™), fremanezumab (Ajovy™), or galcanezumab (Emgality™) is approved when ALL of the following are met:

A. Prescribed by a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties; and
B. Member is 18 years of age or older; and
C. ONE of the following:
   1. Diagnosis of episodic migraines defined as 5-14 headache days per month and inadequate response or inability to tolerate a 4-week trial of TWO of the following prophylactic medications:
      a. Topiramate
      b. Divalproex sodium/ valproic acid
      c. Beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol
      d. Tricyclic antidepressants: amitriptyline, nortriptyline
      e. SNRI antidepressants: venlafaxine, duloxetine
      OR
   2. Diagnosis of chronic migraines defined as 15 or more headache days per month and inadequate response or inability to tolerate ONE of the following:
      a. A 4-week trial of TWO of the following prophylactic medications:
         i. Topiramate
         ii. Divalproex sodium/ valproic acid
         iii. Beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol
         iv. Tricyclic antidepressants: amitriptyline, nortriptyline
         v. SNRI antidepressants: venlafaxine, duloxetine
      OR
      b. Inadequate response or inability to tolerate onabotulinumtoxin A (Botox)

Initial authorization duration: 6 months

**REAUTHORIZATION CRITERIA**

Erenumab (Aimovig™) fremanezumab (Ajovy™), or galcanezumab (Emgality™) is approved when ALL of the following are met:

1. Prescribed by or in consultation with a neurologist or headache specialist
2. Documentation of response to therapy as defined by 50% reduction in headache days per month from baseline (defined as at least 4 hours duration and moderate intensity)

Approval duration: 12 months

» Black Box Warning:
None

» Guidelines:
Refer to the specific manufacturer's prescribing information for administration and dosage details and any applicable Black Box warnings.

BENEFIT APPLICATION

Subject to the terms and conditions of the applicable benefit contract, the applicable drug(s) identified in this policy is (are) covered under the prescription drug benefits of the Company's products when the medical necessity criteria listed in this pharmacy policy are met. Any services that are experimental/investigational or cosmetic are benefit contract exclusions for all products of the Company.

» References:

» Applicable Drugs:
Inclusion of a drug in this table does not imply coverage. Eligibility, benefits, limitations, exclusions, precertification/referral requirements, provider contracts, and Company policies apply.

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aimovig™</td>
<td>Erenumab</td>
</tr>
<tr>
<td>Ajovy™</td>
<td>Fremanezumab</td>
</tr>
<tr>
<td>Emgality™</td>
<td>Galcanezumab</td>
</tr>
</tbody>
</table>

» Cross References:
Botulinum toxin agents 08.00.26s (medical policy)
Policy Version Number: 3.00
P&T Approval Date: October 11, 2018
Policy Effective Date: October 12, 2018
Next Required Review Date: April 26, 2019

The Policy Bulletins on this web site were developed to assist the Company in administering the provisions of the respective benefit programs, and do not constitute a contract. If you have coverage through the Company, please refer to your specific benefit program for the terms, conditions, limitations and exclusions of your coverage. Company does not provide health care services, medical advice or treatment, or guarantee the outcome or results of any medical services/treatments. The facility and professional providers are responsible for providing medical advice and treatment. Facility and professional providers are independent contractors and are not employees or agents of the Company. If you have a specific medical condition, please consult with your doctor. The Company reserves the right at any time to change or update its Policy Bulletins.